Search results
3 lis 2020 · A panel of 15 international experts in the treatment of MG was convened and, in 2016, published an international consensus guidance for the management of MG. 1. Results of several new trials of MG treatment have been published since that guidance statement was published, and in 2019, the panel reviewed the previous recommendations for currency ...
Myasthenia gravis is an autoimmune disease, which means the immune system—which normally protects the body from foreign organisms—mistakenly attacks itself. Myasthenia gravis is caused by an error in the transmission of nerve impulses to muscles.
Objective. To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. Methods. In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened.
Myasthenia gravis is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence based medicine.
Acquired myasthenia gravis (MG) is a disorder of neuromuscular transmission, resulting from binding of autoantibodies to components of the neuromuscular junction, most commonly the acetylcholine receptor (AChR).
Myasthenia Gravis (MG) is a neuromuscular transmission disorder characterized by fluctuating weakness and fatigability of voluntary muscles (ocular, bulbar, limbs, neck and respiratory) without loss of reflexes or impairment of sensation or other neurologic function.
M yasthenia gravis (MG) is the most common disorder of the neuromuscular junction. In MG, autoantibodies directed against various components of the postsynaptic muscle membrane result in characteristic fatigable weakness of ocular, bulbar, respiratory, axial, and limb muscles.
